FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200110886> ?p ?o ?g. }

• W4200110886 abstract "Abstract Rationale High galectin-3 levels predict poor outcomes in patients with COVID-19. Galectin-3 activates monocytes and macrophages which are directly implicated in COVID-19 immunopathology and the cytokine storm. GB0139 is a potent thiodigalactoside galectin-3 inhibitor and may reduce the severe effects of the disease. We report safety and pharmacokinetics and pharmacodynamics of the inhaled galectin-3 inhibitor, GB0139, and assess clinical outcomes and key systemic inflammatory biomarkers in hospitalised patients with COVID-19 (ClinicalTrials.gov/EudraCT identifier: NCT04473053 /2020-002230-32). Methods Adults with COVID-19 requiring oxygen, and with pneumonitis on x-ray, were randomised to receive standard of care (SOC; including dexamethasone; n=21) or SOC plus 10 mg GB0139 twice daily for 48 hours, then once daily for ≤14 days (n=20). Results Patients aged 27–87 years were enrolled from July 2020; the final patient completed the 90-day follow-up in April 2021. GB0139+SOC was well tolerated with no treatment-related serious adverse events reported. Incidences of adverse events were similar between treatment arms (40 with GB0139+SOC vs 35 with SOC). Plasma GB0139 was measurable in all patients after inhaled exposure, with moderate interpatient variability, and demonstrated target engagement with decreased circulating galectin (overall treatment effect post-hoc over days 2–7: p=0·0099 vs SOC). Rate of decline in fraction of inspired oxygen (%) requirement was significantly greater in the GB0139+SOC arm with a posterior mean difference of -1·51 (95% highest posterior density: -2·90, -0·189) versus SOC. Plasma levels of biomarkers associated with inflammation, coagulopathy, major organ function and fibrosis showed a downward trend versus SOC. Conclusions GB0139+SOC was well tolerated and achieved clinically relevant plasma concentrations and target engagement. This, and the reduction in markers associated with inflammatory, coagulation, fibrosis, and reduction in inspired oxygen (%) over SOC alone, indicates the therapeutic potential for inhaled GB0139 in hospitalised patients with COVID-19." @default.
• W4200110886 created "2021-12-31" @default.
• W4200110886 creator A5000184140 @default.
• W4200110886 creator A5006209737 @default.
• W4200110886 creator A5007196646 @default.
• W4200110886 creator A5011577349 @default.
• W4200110886 creator A5028713678 @default.
• W4200110886 creator A5029701342 @default.
• W4200110886 creator A5039938614 @default.
• W4200110886 creator A5040826518 @default.
• W4200110886 creator A5043003994 @default.
• W4200110886 creator A5043439053 @default.
• W4200110886 creator A5043894410 @default.
• W4200110886 creator A5053576296 @default.
• W4200110886 creator A5061749118 @default.
• W4200110886 creator A5063864832 @default.
• W4200110886 creator A5068395945 @default.
• W4200110886 creator A5071446755 @default.
• W4200110886 creator A5072215414 @default.
• W4200110886 creator A5076843523 @default.
• W4200110886 creator A5081027585 @default.
• W4200110886 creator A5081809096 @default.
• W4200110886 date "2021-12-21" @default.
• W4200110886 modified "2023-10-18" @default.
• W4200110886 title "GB0139, an inhaled small molecule inhibitor of galectin-3, in COVID-19 pneumonitis: a randomised, controlled, open-label, phase 2a experimental medicine trial of safety, pharmacokinetics, and potential therapeutic value" @default.
• W4200110886 cites W1424462706 @default.
• W4200110886 cites W1978655989 @default.
• W4200110886 cites W1984439708 @default.
• W4200110886 cites W2003254802 @default.
• W4200110886 cites W2051386131 @default.
• W4200110886 cites W2081415617 @default.
• W4200110886 cites W2135703618 @default.
• W4200110886 cites W2145836265 @default.
• W4200110886 cites W2170468008 @default.
• W4200110886 cites W2281484774 @default.
• W4200110886 cites W2523206592 @default.
• W4200110886 cites W2784906428 @default.
• W4200110886 cites W2903771841 @default.
• W4200110886 cites W3009885589 @default.
• W4200110886 cites W3011749060 @default.
• W4200110886 cites W3014050022 @default.
• W4200110886 cites W3023982717 @default.
• W4200110886 cites W3027630905 @default.
• W4200110886 cites W3034529698 @default.
• W4200110886 cites W3034947721 @default.
• W4200110886 cites W3035939706 @default.
• W4200110886 cites W3036121018 @default.
• W4200110886 cites W3036954258 @default.
• W4200110886 cites W3039456903 @default.
• W4200110886 cites W3041667892 @default.
• W4200110886 cites W3081687852 @default.
• W4200110886 cites W3083163666 @default.
• W4200110886 cites W3086455642 @default.
• W4200110886 cites W3091967082 @default.
• W4200110886 cites W3092490718 @default.
• W4200110886 cites W3094811545 @default.
• W4200110886 cites W3102870960 @default.
• W4200110886 cites W3105832584 @default.
• W4200110886 cites W3108873379 @default.
• W4200110886 cites W3109306856 @default.
• W4200110886 cites W3120200144 @default.
• W4200110886 cites W3120469415 @default.
• W4200110886 cites W3125908954 @default.
• W4200110886 cites W3135341289 @default.
• W4200110886 cites W3137971666 @default.
• W4200110886 cites W3139099468 @default.
• W4200110886 cites W3146053952 @default.
• W4200110886 cites W3164994653 @default.
• W4200110886 cites W3188095235 @default.
• W4200110886 cites W3211546652 @default.
• W4200110886 cites W4206449744 @default.
• W4200110886 cites W4213073926 @default.
• W4200110886 doi "https://doi.org/10.1101/2021.12.21.21267983" @default.
• W4200110886 hasPublicationYear "2021" @default.
• W4200110886 type Work @default.
• W4200110886 citedByCount "5" @default.
• W4200110886 countsByYear W42001108862022 @default.
• W4200110886 countsByYear W42001108862023 @default.
• W4200110886 crossrefType "posted-content" @default.
• W4200110886 hasAuthorship W4200110886A5000184140 @default.
• W4200110886 hasAuthorship W4200110886A5006209737 @default.
• W4200110886 hasAuthorship W4200110886A5007196646 @default.
• W4200110886 hasAuthorship W4200110886A5011577349 @default.
• W4200110886 hasAuthorship W4200110886A5028713678 @default.
• W4200110886 hasAuthorship W4200110886A5029701342 @default.
• W4200110886 hasAuthorship W4200110886A5039938614 @default.
• W4200110886 hasAuthorship W4200110886A5040826518 @default.
• W4200110886 hasAuthorship W4200110886A5043003994 @default.
• W4200110886 hasAuthorship W4200110886A5043439053 @default.
• W4200110886 hasAuthorship W4200110886A5043894410 @default.
• W4200110886 hasAuthorship W4200110886A5053576296 @default.
• W4200110886 hasAuthorship W4200110886A5061749118 @default.
• W4200110886 hasAuthorship W4200110886A5063864832 @default.
• W4200110886 hasAuthorship W4200110886A5068395945 @default.
• W4200110886 hasAuthorship W4200110886A5071446755 @default.
• W4200110886 hasAuthorship W4200110886A5072215414 @default.
• W4200110886 hasAuthorship W4200110886A5076843523 @default.
• W4200110886 hasAuthorship W4200110886A5081027585 @default.
• W4200110886 hasAuthorship W4200110886A5081809096 @default.
• W4200110886 hasBestOaLocation W42001108861 @default.

• next